Medicus Pharma Closes $4.25 Million Equity Financing And $10.5 Million Debt Exchange

Medicus Pharma has closed $4.25 million in equity financings and exchanged $10.5 million in debt for preferred shares, strengthening its balance sheet as it advances its precision oncology strategy.

The equity financing includes a $3 million registered direct offering and a $1.25 million private placement led by executives and other insiders.

Executive Chairman and CEO Dr. Raza Bokhari invested $750,000 through an entity he controls.

Both financings were priced at an effective $1.72 per common share. The registered offering included common shares and pre-funded warrants, while the private placement consisted of restricted common shares.

Proceeds will support working capital and development priorities, including the investigational CD228V antibody-drug conjugate, and may also fund debt repayment.

Streeterville Capital exchanged $10.5 million of outstanding indebtedness for 105,000 preferred shares issued at $100 each.

The preferred shares are non-convertible and generally non-voting. They carry an 8% cumulative annual dividend payable in kind and are redeemable at Medicus’s option, without a holder redemption right.

The exchange generated no cash proceeds, and any debt not exchanged remains outstanding.

Together with approximately $350,000 raised through its at-the-market program since September 30, Medicus believes the transactions lifted shareholders’ equity above Nasdaq’s $2.5 million continued-listing threshold. Compliance remains subject to Nasdaq confirmation.

Following the financings, Bokhari controls approximately 18.3% of outstanding common shares on a non-diluted basis.

Maxim Group advised on the registered direct offering.

Medicus’s development portfolio includes CD228V, SkinJect for basal cell carcinoma lesions in Gorlin Syndrome and Teverelix for several potential indications.

Its strategy focuses on advancing selected programs through proof-of-concept and regulatory milestones before pursuing licensing, co-development and other partnerships.